Continuous Glucose Monitoring for Type 2 Diabetes
(TEAM-CGM Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude those using steroids or planning to use prescription weight loss medications. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the treatment Community Health Worker, Community Health Worker, CHW, Pharmacist Only for Continuous Glucose Monitoring in Type 2 Diabetes?
Research shows that continuous glucose monitoring (CGM) devices help improve diabetes management by providing detailed glucose trends, which can enhance treatment and safety. Pharmacists are well positioned to support patients in using CGM, as they can offer guidance and collaborate with healthcare providers to help patients achieve their blood sugar goals.12345
Is continuous glucose monitoring safe for humans?
How does the Pharmacist Only treatment for Type 2 Diabetes differ from other treatments?
The Pharmacist Only treatment involves the use of continuous glucose monitoring (CGM) devices managed by pharmacists, which is unique because it allows for real-time glucose tracking and personalized diabetes management in community and ambulatory care settings. This approach leverages pharmacists' expertise to improve patient outcomes by closely monitoring glucose levels and adjusting treatment plans accordingly.14568
What is the purpose of this trial?
Continuous glucose monitoring (CGM) can help improve blood sugar management in type 2 diabetes. A sequential, multiple assignment, randomized trial will evaluate clinical pharmacists, community health workers, and telehealth in supporting CGM use to improve blood sugar control.
Research Team
Ben Gerber, MD, MPH
Principal Investigator
University of Massachusetts, Worcester
Eligibility Criteria
This trial is for adults aged 25-75 with type 2 diabetes for over a year, who speak English or Spanish. Participants must have an A1c level of at least 9% in the past six months and be willing to use continuous glucose monitoring (CGM) and work with health workers.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Treatment
Participants receive clinical pharmacist support and continuous glucose monitoring (CGM) for diabetes management
Re-randomization and Extended Treatment
Participants not meeting HbA1c goals are re-randomized to receive additional community health worker (CHW) support along with pharmacist and CGM support
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Community Health Worker
- Pharmacist Only
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Massachusetts, Worcester
Lead Sponsor
Baystate Health
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Family Health Center of Worcester
Collaborator